MPNs

JAK Inhibition for the Management of Primary Myelofibrosis

Primary Myelofibrosis

Polycythemia Vera

Srdan Verstovsek, MD, PhD, discusses the use of ruxolitinib as a second-line treatment of patients with polycythemia vera.

In an analysis comparing real-life outcomes, interferon-a demonstrated more profound hematologic responses compared with hydroxyurea in select patients with myeloproliferative neoplasms. Additionally, molecular responses to therapy were limited to those patients who received IFN-a.

A new phase III trial has demonstrated that a novel extended-release formulation of anagrelide (Thromboreductin) is noninferior to immediate-release anagrelide in reducing platelet counts in patients with essential thrombocythemia.

Srdan Verstovsek, MD, PhD, discusses the use of interferon in MPNs, including essential thrombocythemia, polycythemia vera, and myelofibrosis.

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in patients with polycythemia vera.

Diagnosis, risk stratification, and the management of patients with polycythemia vera and myelofibrosis have all been significantly improved by the inclusion of a greater understanding of the clinical and molecular characteristics of these 2 different myeloproliferative neoplasms, according to Abdulraheem Yacoub, MD.